Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Study ID
- NCT00370851
- Phase
- PHASE3
- Status
- Completed
Conditions
- Retinal Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 40 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Avastin (Bevacizumab) — DRUGIntravitreal injection of 125 mg Avastin
Study Details
In this study we intend to evaluate the outcome of intravitreal avastin on improving the visual acuity and macular edema and late complications of BRVO like NVD and NVE
Key Dates
- First listed
- Sep 1, 2006
- Start date
- Aug 31, 2006
- Status verified
- Nov 2009
- Primary completion
- Feb 29, 2008
- Completion
- Jun 30, 2008
Study Design
- Enrollment
- 82 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: 1Intravitreal injection of Avastin
- Sham Comparator: 2
Primary Outcome Measure
Best corrected visual acuity [ Time Frame: At 12 week ]
Related Studies
- Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 GeneRecruiting · National Eye Institute (NEI) · Bethesda, Maryland
- Cell Collection to Study Eye DiseasesRecruiting · National Eye Institute (NEI) · Bethesda, Maryland
- National Eye Institute Biorepository for Retinal DiseasesRecruiting · National Eye Institute (NEI) · Bethesda, Maryland
- Inherited Retinal Degenerative Disease RegistryRecruiting · Foundation Fighting Blindness · Columbia, Maryland